H. Döhner, E. Estey, D. Grimwade, S. Amadori, F. R. Appelbaum et al., Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel, Blood, vol.129, issue.4, pp.424-447, 2017.

S. F. Cai and R. L. Levine, Genetic and epigenetic determinants of AML pathogenesis, Semin Hematol, vol.56, issue.2, pp.84-93, 2019.

H. J. Iland, Curative strategies in APL, Semin Hematol, vol.56, issue.2, pp.131-139, 2019.

B. Deschler and M. Lübbert, Acute myeloid leukemia: Epidemiology and etiology, Cancer, vol.107, issue.9, pp.2099-107, 2006.

L. Guyader-peyrou, S. Belot, A. Maynadié, M. Binder-foucard, F. Remontet et al., Cancer incidence in France over the 1980-2012 period: Hematological malignancies, Rev Epidemiol Sante Publique, vol.64, issue.2, pp.103-112, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01511580

H. Döhner, D. Weisdorf, and C. Bloomfield, Acute Myeloid Leukemia, N Engl J Med, issue.373, pp.1136-52, 2015.

K. R. Rai, J. F. Holland, O. J. Glidewell, V. Weinberg, K. Brunner et al., Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B, Blood, vol.58, issue.6, pp.1203-1212, 1981.

J. M. Rowe and M. S. Tallman, How I treat acute myeloid leukemia, Blood, vol.116, issue.17, pp.3147-3156, 2010.

T. Büchner, W. E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger et al., Age-Related Risk Profile and Chemotherapy Dose Response in Acute Myeloid Leukemia: A Study by the German Acute Myeloid Leukemia Cooperative Group, J Clin Oncol, vol.27, issue.1, pp.61-70, 2009.

P. Ferguson, R. K. Hills, A. Grech, S. Betteridge, L. Kjeldsen et al., An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation, Haematologica, vol.101, issue.11, pp.1351-1359, 2016.

B. Gyurkocza, H. M. Lazarus, and S. Giralt, Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy, Bone Marrow Transplant, vol.52, issue.8, pp.1083-90, 2017.

J. Versluis and J. J. Cornelissen, Risks and benefits in a personalized application of allogeneic transplantation in patients with AML in first CR, Semin Hematol, vol.56, issue.2, pp.164-70, 2019.

F. Buccisanoa and R. Walter, Should patients with acute myeloid leukemia and measurable residual disease be transplanted in first complete remission?, Curr Opin Hematol, vol.2017, issue.24, pp.132-138

D. Barnes, M. J. Corp, J. F. Loutit, and F. E. Neal, Treatment of murine leukaemia with x rays and homologous bone marrow, Br Med J, vol.2, issue.4993, p.626, 1956.

E. Thomas, H. Lochte, W. C. Lu, and J. Ferrebee, Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy, N Engl J Med, vol.257, issue.11, pp.491-96, 1957.

U. D. Bayraktar, D. R. Milton, M. Guindani, G. Rondon, J. Chen et al., Optimal Threshold and Time of Absolute Lymphocyte Count Assessment for Outcome Prediction after Bone Marrow Transplantation, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.22, issue.3, pp.505-518, 2016.

K. Bogunia-kubik, From genetic single candidate gene studies to complex genomics of GvHD, Br J Haematol, vol.178, issue.5, pp.661-675, 2017.

A. Amouzegar, B. R. Dey, and T. R. Spitzer, Peripheral Blood or Bone Marrow Stem Cells? Practical Considerations in Hematopoietic Stem Cell Transplantation, Transfus Med Rev, 2018.

C. Cutler, S. Giri, S. Jeyapalan, D. Paniagua, A. Viswanathan et al., Acute and Chronic Graft-Versus-Host Disease After Allogeneic Peripheral-Blood Stem-Cell and Bone Marrow Transplantation: A Meta-Analysis, J Clin Oncol, vol.19, issue.16, pp.3685-91, 2001.

P. M. Armistead, M. De-lima, S. Pierce, W. Qiao, X. Wang et al., Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.15, issue.11, pp.1431-1439, 2009.

C. Schmid, M. Schleuning, G. Ledderose, J. Tischer, and H. Kolb, Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome, J Clin Oncol Off J Am Soc Clin Oncol, vol.23, issue.24, pp.5675-87, 2005.

R. Duléry, A. Ménard, S. Chantepie, J. El-cheikh, S. François et al., Sequential Conditioning with Thiotepa in T Cell-Replete Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematologic Malignancies: Comparison with Matched Related, Haplo-Mismatched, and Unrelated Donors, Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant, vol.24, issue.5, pp.1013-1034, 2018.

H. M. Schoemans, S. J. Lee, J. L. Ferrara, D. Wolff, J. E. Levine et al., EBMT?NIH?CIBMTR Task Force position statement on standardized terminology & guidance for graft-versus-host disease assessment, Bone Marrow Transplant, vol.53, issue.11, p.1401, 2018.

S. J. Lee, Classification systems for chronic graft-versus-host disease, Blood, vol.129, issue.1, pp.30-37, 201705.

J. C. Biggs, M. M. Horowitz, R. P. Gale, R. C. Ash, K. Atkinson et al., Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy, Blood, vol.80, issue.4, pp.1090-1093, 1992.

M. Duval, J. P. Klein, W. He, J. Cahn, M. Cairo et al., Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure, J Clin Oncol, vol.28, issue.23, pp.3730-3738, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00849640

E. Todisco, F. Ciceri, C. Boschini, F. Giglio, A. Bacigalupo et al., Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant, vol.52, pp.955-61, 2017.

S. Frohling, R. F. Schlenk, S. Kayser, M. Morhardt, A. Benner et al., Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood, vol.108, pp.3280-3288, 2006.

E. Brissot, M. Labopin, M. Stelljes, G. Ehninger, R. Schwerdtfeger et al., Comparison of matched sibling donors versus unrelated donors in allogeneic stem cell transplantation for primary refractory acute myeloid leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT, J Hematol OncolJ Hematol Oncol, vol.10, issue.1, pp.130-140, 2017.

D. Schneidawind, B. Federmann, C. Faul, W. Vogel, L. Kanz et al., Allogeneic hematopoietic cell transplantation with reduced-intensity conditioning following FLAMSA for primary refractory or relapsed acute myeloid leukemia, Ann Hematol, vol.92, issue.10, pp.1389-95, 2013.

C. Craddock, M. Labopin, S. Pillai, J. Finke, D. Bunjes et al., Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia, Leukemia, vol.25, issue.5, pp.808-821, 2011.

J. Ogonek, K. Juric, M. Ghimire, S. Varanasi, P. R. Holler et al., Immune reconstitution after allogeneic hematopoietic stem cell transplantation, Front Immunol, vol.7, p.507, 2016.

D. Tian, Y. Wang, X. Zhang, K. Liu, X. Huang et al., Rapid recovery of CD3+ CD8+ T cells on day 90 predicts superior survival after unmanipulated haploidentical blood and marrow transplantation, PloS One, vol.11, issue.6, p.156777, 2016.

J. M. Middeke, R. Herbst, S. Parmentier, G. Bug, M. Hänel et al., Long-Term Follow-Up and Impact of Comorbidity before Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Myeloid Leukemia-Lessons Learned from the Prospective BRIDGE Trial, Biol Blood Marrow Transplant, vol.23, issue.9, pp.1491-1498, 2017.

M. Sorror, B. Logn, X. Zhu, D. Rizz, K. Cooke et al., Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A CIBMTR® Study, Biol Blood Marrow Transplant, vol.21, issue.8, pp.1479-1487, 2015.

P. G. Hemmati, T. H. Terwey, I. Na, C. F. Jehn, P. Le-coutre et al., Allogeneic stem cell transplantation for refractory acute myeloid leukemia: a single center analysis of long-term outcome, Eur J Haematol, vol.95, issue.6, pp.498-506, 2015.

H. Ogawa, K. Ikegame, T. Daimon, N. Uchida, T. Fukuda et al., Impact of pretransplant leukemic blast% in bone marrow and peripheral blood on transplantation outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation in non-CR, Bone Marrow Transplant, vol.53, issue.4, pp.478-82, 2018.

C. Schmid, Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation, Blood, vol.108, issue.3, pp.1092-1101, 2006.

A. Nagler, B. N. Savani, M. Labopin, E. Polge, J. Passweg et al., Outcomes after use of two standard ablative regimens in patients with refractory acute myeloid leukaemia: a retrospective, multicentre, registry analysis, Lancet Haematol, vol.2, issue.9, pp.384-92, 2015.

C. Schmid, Refractory AML -The transplanter's perspective. European Society for Blood and Marrow Transplantation, 2019.

M. Slade, J. F. Dipersio, P. Westervelt, R. Vij, M. A. Schroeder et al., Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome, Biol Blood Marrow Transplant, vol.23, issue.10, pp.1736-1779, 2017.

B. Gu, X. Zhang, G. Chen, X. Wu, X. Ma et al., Efficacy of haploidentical hematopoietic stem cell transplantation compared to HLA-matched transplantation for primary refractory acute myeloid leukemia, Ann Hematol, vol.97, issue.11, pp.2185-94, 2018.

V. R. Bhatt and S. O. Ciurea, Haploidentical Transplants for Acute Myeloid Leukemia in Adults. Haploidentical Transplantation, Advances and Controversies in Hematopoietic Transplantation and Cell Therapy, vol.2018, pp.231-243

E. Brissot, M. Labopin, G. Ehninger, M. Stelljes, A. Brecht et al., Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT, Haematologica, vol.104, issue.3, pp.524-556, 2019.

C. Pfrepper, A. Klink, G. Behre, T. Schenk, G. Franke et al., Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation, J Cancer Res Clin Oncol, vol.142, issue.1, pp.317-341, 2016.

J. Yang, Y. Cai, J. Jiang, L. Wan, H. Bai et al., Early tapering of immunosuppressive agents after HLA-matched donor transplantation can improve the survival of patients with advanced acute myeloid leukemia, Ann Hematol, vol.97, issue.3, pp.497-507, 2018.

C. Craddock, M. Labopin, M. Robin, J. Finke, P. Chevallier et al., Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia, Haematologica, vol.101, issue.7, pp.879-83, 2016.

C. Schmid, M. Labopin, N. Schaap, H. Veelken, M. Schleuning et al., Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia -a matched pair analysis by the Acute Leukaemia Working Party of EBMT, Br J Haematol, vol.184, issue.5, pp.782-789, 2019.

U. Gergis, G. Roboz, T. Shore, R. E. Mayer, S. Wissa et al., A phase I study of CPX-351 in combination with busulfan and fludarabine conditioning and allogeneic stem cell transplantation in adult patients with refractory acute leukemia, Biol Blood Marrow Transplant, vol.19, issue.7, pp.1040-1045, 2013.

. Tiong, . Is, and A. H. Wei, New drugs creating new challenges in acute myeloid leukemia, Genes Chromosomes Cancer, vol.1, pp.1-12, 2019.

P. Bose, P. Vachhani, and J. E. Cortes, Treatment of relapsed/refractory acute myeloid leukemia, Curr Treat Options Oncol, vol.18, issue.3, p.17, 2017.

K. D. Cummins and S. Gill, Will CAR T cell therapy have a role in AML? Promises and pitfalls, Semin Hematol, vol.56, issue.2, pp.155-63, 2019.